COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America..
We investigated whether the antibody response to coronavirus disease 2019 (COVID-19) mRNA vaccination is similar in women and men. In a community cohort without prior COVID-19, first vaccine dose produced higher immunoglobulin G (IgG) levels and percent inhibition of spike-ACE2 receptor binding, a surrogate measure of virus neutralization, in women compared to men (7.0 µg/mL, 51.6% vs 3.3 µg/mL, 36.4%). After 2 doses, IgG levels remained significantly higher for women (30.4 µg/mL) compared to men (20.6 µg/mL), while percent inhibition was similar (98.4% vs 97.7%). Sex-specific antibody response to mRNA vaccination informs future efforts to understand vaccine protection and side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:224 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 224(2021), 5 vom: 01. Sept., Seite 793-797 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Demonbreun, Alexis R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2021 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiab314 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326657800 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326657800 | ||
| 003 | DE-627 | ||
| 005 | 20231227130526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiab314 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM326657800 | ||
| 035 | |a (NLM)34117873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Demonbreun, Alexis R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2021 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a We investigated whether the antibody response to coronavirus disease 2019 (COVID-19) mRNA vaccination is similar in women and men. In a community cohort without prior COVID-19, first vaccine dose produced higher immunoglobulin G (IgG) levels and percent inhibition of spike-ACE2 receptor binding, a surrogate measure of virus neutralization, in women compared to men (7.0 µg/mL, 51.6% vs 3.3 µg/mL, 36.4%). After 2 doses, IgG levels remained significantly higher for women (30.4 µg/mL) compared to men (20.6 µg/mL), while percent inhibition was similar (98.4% vs 97.7%). Sex-specific antibody response to mRNA vaccination informs future efforts to understand vaccine protection and side effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ELISA | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a dried blood spots | |
| 650 | 4 | |a neutralizing | |
| 650 | 4 | |a receptor binding domain | |
| 650 | 4 | |a serological testing | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 700 | 1 | |a Sancilio, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Velez, Matt E |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Daniel T |e verfasserin |4 aut | |
| 700 | 1 | |a Pesce, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Saber, Rana |e verfasserin |4 aut | |
| 700 | 1 | |a Vaught, Lauren A |e verfasserin |4 aut | |
| 700 | 1 | |a Reiser, Nina L |e verfasserin |4 aut | |
| 700 | 1 | |a Hsieh, Ryan R |e verfasserin |4 aut | |
| 700 | 1 | |a D'Aquila, Richard T |e verfasserin |4 aut | |
| 700 | 1 | |a Mustanski, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a McDade, Thomas W |e verfasserin |4 aut | |
| 700 | 1 | |a McNally, Elizabeth M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 224(2021), 5 vom: 01. Sept., Seite 793-797 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:224 |g year:2021 |g number:5 |g day:01 |g month:09 |g pages:793-797 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiab314 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 224 |j 2021 |e 5 |b 01 |c 09 |h 793-797 | ||